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Abstract   
Background: There are few data describing the HIV epidemic among men who have 
sex with men (MSM) in South Africa, and thus little information is available to inform 
appropriate public health response strategies for this high-risk group. One such existing 
knowledge gap is an understanding of HIV transmission patterns between different MSM 
communities and between MSM and the heterosexual population. Studies in the early 
1990s identified two independent HIV-1 epidemics in Cape Town: a predominantly 
subtype B epidemic among white MSM and the mainly subtype C epidemic among the 
predominantly black heterosexual epidemic. While the heterosexual epidemic remains 
primarily due to subtype C virus, few recent HIV-1 subtype data are available for MSM in 
South Africa. This study examined circulating HIV-1 subtypes among MSM in Cape 
Town.    
 
Methods: Self-identified MSM were recruited from geographically and racially disparate 
communities across Cape Town. A trained interviewer administered a study 
questionnaire, eliciting information on demographic characteristics, sexual orientation, 
and sexual partners. Participants underwent HIV counselling and testing, and CD4 T-cell 
count and HIV subtype testing was performed on HIV-infected participants. Subtyping 
was performed by DNA amplification followed by nucleotide sequencing of the complete 
env gp160 gene. HIV-1 subtypes were assigned via phylogenetic analysis.  
 
Results: In total 194 HIV-infected MSM were enrolled: 52% were from communities that 
were historically designated as black African and/or coloured communities. The majority 
of the participants were black African (67%), with 24% coloured, and 9% white men. 
More black African men identified as bisexual or heterosexual compared to other races. 
Overall 40% of men reported a recent partner of a different race. HIV-1 subtypes were 
confirmed for 143 participants: 81% were subtype C, 14% B, 1% A1, 1% F2, and three 
recombinant viruses.  Subtype C virus was associated with black African race (p=0.003 
compared to coloured; p<0.001 compared to white), men who identified as 
bisexual/heterosexual (p=0.01), and who reported a female sexual partner in the last 
year (p=0.02).  Compared to previous studies, an increasing prevalence of subtype C 













Conclusions: This molecular epidemiological study provides novel evidence of sexual 
network links between the heterosexual and MSM epidemics and between previously 
racially disparate communities in Cape Town. These data concur with behavioural 
evidence of links between these epidemics and communities. This study provides 
insights into the drivers of HIV epidemics in different population groups and may have 
implications for prevention strategies and research, particularly the development of 
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Protocol for epidemiological study of HIV-1 subtypes among Cape Town MSM 
 
Design: Cross-sectional survey 
 
Duration: 9 months: Clinical component: Recruitment and 
enrolment 
6 months: Laboratory component: Sequencing and 
sequence analysis 
Sample Size: 200 HIV-infected participants 
Population:  Self-identified MSM, 16 years or older, resident in 
urban and peri-urban Cape Town and sexually 
active with a male partner in the last 12 months. 
Participants must be willing and able to provide 
written informed consent and undergo HIV testing.  
Primary Study Objective:  To identify HIV-1 subtypes present among HIV-
infected MSM in historically racially defined 
geographical areas (urban and peri-urban) in the 
greater Cape Town area. 
Secondary Study Objectives: To investigate associations between race and HIV-1 
subtypes among MSM in the greater Cape Town 
area. 
To determine the extent of possible sexual network 
links between urban and peri-urban MSM 
populations in the greater Cape Town area 
To determine the extent of possible sexual network 
links between the MSM population and the general 
















II. Background and Significance 
Nearly three decades after the discovery of HIV, this pathogen remains a major cause of 
morbidity and mortality worldwide. The UNAIDS estimated that globally 34 million people 
were living with HIV by the end of 2010, with a further 2.7 million people newly infected 
in the same year [1].  
A key characteristic of HIV is the genetic diversity of the virus, which is classified into a 
number of groups and subtypes. The global pandemic is comprised predominantly of 
HIV-1 Group M infections. Group M is further divided into a number of subtypes or 
clades [2,3], of which HIV-1 subtype C is responsible for the bulk of infections globally 
[4]. 
 
2.1  HIV Diversity 
To date nine subtypes of HIV-1 group M have been identified: A-D, F-H, J and K [4], as 
well as a large number of recombinant viruses and circulating recombinant forms (CRF) 
[4,5]. The genetic diversity between subtypes and recombinant viruses of HIV-1 may 
have several important implications for patient care.  
Genetic diversity has shown to affect the validity of HIV-1 serology tests [6] as 
well as certain viral load tests [7,8]. HIV-1 subtypes may vary in transmissibility [9], in 
proficiency of spread by specific routes [10-12], and in progression to AIDS [13-17].  
There is a growing body of evidence that HIV genetic variability has the potential 
to impact on susceptibility and response to antiretroviral (ARV) drugs [13], including non-
nucleoside reverse transcriptase inhibitors (NNRTIs) [18] and protease inhibitors (PIs) 
[19,20]. Subtype diversity may be an important factor in the effectiveness of new classes 
of ARV drugs, targeting viral attachment or cell entry.  Subtypes are associated with 
different co-receptor phenotype strains [21,22] and these variations may mean that new 
drugs such as CCR5 antagonists have limited benefit in some viral subtypes [23]. In 
addition, these findings support the hypothesis that subtypes may differ with regards to 
virulence and transmissibility [21]. HIV-1 diversity may also impact the type of drug 
resistance mutations, the rate of resistance emergence as well as cross-resistance to 
ARVs within drug classes [24]. There is strong evidence that subtypes acquire different 
ARV drug resistance patterns [25], including resistance mutations to nucleoside reverse 













Furthermore, in the field of HIV prevention HIV subtypes may play an important role, 
specifically with regards to vaccine development. The substantial genetic diversity 
between subtypes [36] may limit the cross-reactivity of vaccine-induced immune 
responses [37,38]. In order to determine the implications of HIV subtype for vaccine 
design, vaccines constructed from a variety of subtypes need to be tested in different 
areas or populations, where the subtype distributions are known.  
 
2.2  South African HIV Epidemic 
With an estimated 5.6 million South Africans living with HIV, South Africa has the largest 
HIV epidemic in the world [39]. The history of HIV in South Africa is fascinating, with two 
independent epidemics noted in early reports.  
 
The first cases of Acquired Immune Deficiency Syndrome (AIDS) in South Africa were 
documented in homosexual men in 1982 [40]. Throughout the 1980s the HIV epidemic 
was concentrated mainly in white homosexual males [41]. However, in 1987 the first 
cases of AIDS in heterosexual patients were reported [42] and by the early 1990s the 
demographic profile of the HIV epidemic was changing, with an increasing number of 
black African, heterosexual patients attending South African HIV clinics [41,43]. By the 
mid-1990s the homosexual epidemic had been eclipsed by the far larger heterosexual 
epidemic, the face of which was predominantly black [43]. In the early 1990s the 
country’s focus had shifted to the growing heterosexual epidemic, as epitomised by 
national HIV surveillance being performed in antenatal clinics [42,44].  
 
A molecular epidemiological study of circulating HIV strains in Cape Town in the mid-
1990s suggested that the epidemics among men-who-have-sex-with-men (MSM) and 
heterosexual individuals were independent of one another. The homosexual epidemic 
was comprised almost exclusively of HIV-1 subtype B [45,46], and was strongly 
associated with travel history to the United States of America and Europe [41], regions in 
which this subtype was and remains the dominant virus. The heterosexual epidemic, by 
contrast, comprised predominantly of HIV-1 subtype C [45,46]. This is the most 
prevalent HIV-1 subtype in Southern Africa, and most likely spread to South Africa 













Ongoing surveillance of predominantly heterosexual populations in South African 
townships, including communities in Cape Town, from the late 1990s through the 2000s 
have shown that despite the introduction of other HIV-1 subtypes [47-49], subtype C 
remains responsible for more than 90% of this epidemic [49-53]. While much data are 
available on the general heterosexual HIV epidemic in peri-urban communities, recent 
data on the MSM HIV subtypes and infection patterns are lacking.   
 
2.3  MSM Community 
The phenomenon of MSM includes any male who engages in sexual activity with 
another male.  This is a varied group that includes men who identify as homosexual, 
bisexual and even self-identified heterosexual men.  MSM have a high risk of HIV 
acquisition, due to a number of biological, behavioural and social risk factors [54-56].  
 
During the apartheid era, homosexuality was illegal in South Africa under Common Law 
and punishable by imprisonment. Despite the decriminalisation of homosexuality in 1994 
[57], stigma, social prejudices and human rights abuses remain prevalent [56,58], 
particularly in black African townships where cultural norms are typically not accepting of 
MSM activity. As a result of this social vulnerability black African MSM are less likely to 
be open about their sexual preferences [58] and frequently go to considerable lengths to 
avoid being identified as homosexuals. Even among self-identified MSM, South African 
studies have reported that 4-32% of participants identify as heterosexual or straight [59-
61]. In one study among black African MSM in Cape Town only 1% identified as 
bisexual, but 8% reported being married [56].  
 
In addition, two apartheid legislations, Group Areas Act [62] and the Immorality Act [63] 
enforced racial segregation of the population by delineating residential areas by race, 
and prohibiting inter-race sexual relations, respectively. These acts were abolished in 
the transition to a democratic constitution, allowing for increased socialisation across 
previous geographical and racial divides. However, there are limited data on the impact 
of these legislative, and consequently social, changes on the HIV epidemics among 















2.4  Study Rationale 
Despite the world’s largest HIV treatment programme, HIV/AIDS was still responsible for 
314,000 deaths in South Africa in 2010 [39]. The South African Government, private and 
public sectors have placed a high priority on the development of novel interventions that 
are effective in preventing the transmission of HIV and the provision of timely access to 
antiretroviral treatment when indicated.  While programmes that focus on the general 
South African epidemic are important, the emphasis of HIV programmes on 
heterosexual transmission of HIV has culminated in the neglect of the MSM epidemic 
over the past two decades.  There is growing evidence that HIV prevalence remains high 
in MSM groups in South Africa [60,61], and while the impact of homosexual transmission 
of HIV on the South African epidemic overall is likely minor, these transmission patterns 
may constitute a significant proportion of incident HIV infections among males generally 
[64,65]. Therefore, it is not only unethical but also shortsighted to neglect this vulnerable 
population in national plans for HIV prevention and treatment. 
 
Over the last few years there has been an increasingly loud call for improved 
surveillance and access to safe, appropriate HIV care for MSM in Africa [66], including 
South Africa [60,61]. The South African government has identified MSM as a key 
population for targeted interventions in the current National Strategic Plan on HIV, STIs 
and TB [64]. However, the maxim “Know your epidemic, know your response” [67] is 
particularly apt in this context. Little data are available on the dynamics of the MSM 
epidemics in South Africa, and governments are left to plan HIV response strategies in 
this void.  
 
Given the potential impact of genetic diversity on HIV-1 transmission [9] and disease 
progression [13-17], response to ART [13,19,20], development of ARV drug resistance 
[25-35]  and the efficacy of biomedical HIV prevention interventions [37,38], ongoing 
surveillance of HIV subtype distribution in the South African epidemic is essential.  
 
In South Africa, both the historic, geographical segregation of communities based on 
race and the different cultural backgrounds of these communities may have influenced 
how different MSM groups identified, engaged in MSM activity and interacted both 












democracy, and the legalization of homosexual activity in the South African constitution, 
may have modified these interactions.   
 
An improved understanding of HIV transmission patterns among MSM as well as the 
presence of possible bridging of the epidemics both between the different MSM 
communities and between this population group and the heterosexual population is 
required. This knowledge together with accurate data on HIV subtype distribution may 
increase our understanding of the drivers of our local epidemic, and inform local policy 
and resource allocation and guide HIV prevention initiatives. 
 
This protocol aims to describe the HIV-1 epidemic among MSM in Cape Town, to 
determine if this epidemic remains predominantly due to HIV-1 subtype B and to 
investigate for evidence of bridging between the two previously distinct HIV epidemics in 
Cape Town.   
 
III. Study Overview 
3.1  Hypothesis 
The HIV-1 epidemic among urban MSM is comprised of predominantly subtype B virus, 
while the HIV-1 epidemic among peri-urban MSM is comprised of predominantly subtype 
C virus. 
 
3.2  Study Objectives 
Primary Objective: 
1) To identify HIV-1 subtypes present among HIV-infected MSM in historically 




1) To investigate associations between race and HIV-1 subtypes among MSM in 
the greater Cape Town area. 
2) To determine the extent of possible sexual network links between urban and peri-
urban MSM populations in the greater Cape Town area 
3) To determine the extent of possible sexual network links between MSM 













3.3  Study Design  
A cross-sectional survey among self-identified MSM resident in the greater Cape Town 
area. This study will be nested within a parent study that aims to explore HIV knowledge 
and risk behaviours among HIV-positive and HIV-negative MSM in the greater Cape 
Town area.  
 
3.4  Study Population  
200 HIV-infected MSM, resident in urban and peri-urban Cape Town. 
Urban areas are defined as Cape Town’s Central Business District (CBD) and 
surrounding communities that were historically designated as white areas, such 
as Claremont and Belville. 
Peri-urban areas are defined as township or low-income areas that were 
historically designated as black and/or coloured areas, such as Khayelitsha and 
Mitchell’s Plain.  
 
By recruiting from these two areas, we anticipate enrolment of MSM across the three 
main racial groups in Cape Town: black African, coloured and white. These racial 
categories are in keeping with the terms employed in the 2011 South African census 
[69]. 
Inclusion Criteria 
Participants must meet the following inclusion criteria: 
 Male sex (at birth) 
 Age 16 years or older 
 Reside in the greater Cape Town area 
 Have had anal intercourse with another male in the previous 12 months 
 Willing and able to provide written informed consent to participate in the study 
Exclusion Criteria 
Participants are ineligible for the study if they are: 
 Unwilling to undergo HIV testing 















3.5  Study Duration 
Recruitment and enrolment will occur over a nine month period. Participation will involve 
one or two study visits, not more than one month apart. The subtyping component will 
commence once all specimens are collected, and will be completed in a further six 
months. 
 
3.6  Study Procedures 
2.6.1  Recruitment of Participants 
Preliminary background exploration has been conducted by the Desmond Tutu HIV 
Foundation (DTHF) to identify lesbian, gay, bisexual and transgender (LGBT) venues and 
methods for recruiting research participants into cross-sectional surveys.  Sources of 
information include key informant interviews with local leaders, non-governmental 
organizations (NGOs), and discussions with community advisory boards.   
 
The recruitment strategy for this study will include two components: 
 Fieldworker community-based recruitment 
 Identification during screening for other studies  
 
Fieldworker community-based recruitment 
As MSM are a hard-to-reach population for research, especially in peri-urban communities, 
recruitment strategies previously shown to be successful in such populations, will be 
utilized [70]. 
 
Trained recruiters will visit different organizations and venues frequented by MSM for 
facility-based recruitment.  Peer recruiters will provide presentations to the organizations’ 
staff and potential participants, including an explanation of the study and an invitation to 
participate.  Examples of venues for recruitment activity are saunas, adult movie theaters, 
adult video arcades, areas for commercial sex work (streets, parks, and avenues), 
discotheques, MSM-friendly bars/shebeens (informal township taverns), beauty 
parlors/houses, athletic facilities, open houses, open community meetings and 
entertainment events.  At appropriate venues, recruiters will request the manager’s 












material for customers and organize meetings to publicize the study.  Study recruitment 
may also be done via the internet and social media. 
 
Fieldworker recruitment will utilize a quasi-snowballing recruitment methodology, in which 
MSM participants will be asked to refer other known MSM individuals to join the study.  
This method of sampling is well established in the literature as a tool to recruit hard-to-
reach or marginalized populations, including MSM communities [71-73].  
 
Other studies 
The DTHF study sites are involved in multiple research projects.  Individuals who screen for 
other studies are offered the opportunity to sign an informed consent that authorizes 
investigators to contact them for future research.  Locator information will be available 
for those who gave permission for future contact and recruiters will contact potentially 
eligible participants by telephone or email as specified in the consent. 
 
2.6.2  Screening and Enrolment 
Before written informed consent is sought, all participants will be given information 
regarding the study objectives, procedures, and outcomes.  Any issues will be discussed 
and all questions about the study will be answered.  After the informed consent form has 
been read by the participant, written consent to enrol in the study will be sought.  The 
informed consent form will be available in English, Xhosa and Afrikaans.  Those 
participants who are unable to read the form will have it read to them by an independent 
witness.  Two copies of the informed consent form will be signed: one copy will be given 
to the participant and a copy will remain in the study site file. 
 
2.6.3  Study Procedures 
Questionnaire Completion 
A trained interviewer will administer the study questionnaire in the participant’s home 
language. The questionnaire will include questions on: 
- Demography, including race 
- Sexual orientation 














Validation and reliability 
The questionnaire is not a validated tool. However, the questions were chosen to allow 
for comparability between other, venue-based MSM surveys completed by the DTHF. 
The questions have been reviewed for appropriateness and language by MSM staff and 
representatives of the MSM communities with which the DTHF engage.  
 
As this study will be nested within a parent study that aimed to enroll both HIV-negative 
and HIV-positive patients HIV status is not an inclusion criterion. The questionnaire will 
be completed prior to HIV testing, to ensure participant answers were not influenced by 
the HIV test result. 
 
HIV testing: 
Participants will have an HIV test using finger-prick rapid antibody screening tests. See 
testing algorithm in Section II:7. All participants will receive appropriate HIV-testing 
counselling.  Participants who test HIV-infected will be ref rred to the closest HIV care 
clinic or to an appropriate MSM-friendly clinic of their choice. 
 
Blood Draw 
Blood draw via venipuncture will be performed by a trained health worker. Blood will be 
drawn for HIV sequencing and subtyping, CD4 T-cell count and, when necessary, 
confirmation of HIV status.   
 
Blood samples from HIV-infected patients will be sent for the following: 
 CD4 T-cell count 
 Plasma extraction and storage for HIV subtyping. 
 
Results of the CD4 T-cell count will be made available to the patient as soon as possible 
via the contact information provided. 
 
3.7  Potential Sources of Bias 
This is a cross-sectional survey and as such we are more likely to sample prevalent, 
rather than incident cases of HIV-1. This may introduce length-bias sampling, limiting our 












MSM is a typically hard to reach population, necessitating innovative recruitment 
strategies. However, in these typically non-random sampling approaches there is a risk 
of oversampling some sexual networks while missing hidden sub-groups, such as 
married MSM. In order to avoid oversampling a few select sexual networks, we will 
recruit widely from a number of different venues, as well as from different types of 
venues. Having identified MSM from a variety of locations, we will then employ a quasi-
snowballing recruitment methodology: in this method enrolled participants recruit new 
participants who then in turn recruit further participants and so on. This is a recognized 
method for attempting to reach more hidden sub-groups within a population. It should be 
noted that the relatively small study sample size may limit our ability to access hidden 
sub-groups in our areas.  
 
The offer of an incentive, although small, may influence men who do not have sex with 
men to enroll in the study, particularly from the lower socio-economic, peri-urban areas. 
While it is not possible to negate this risk entirely, we hop  to mitigate the risk by utilising 
recruiters employed from the MSM communities and by predominantly recruiting from 
MSM-frequented venues.  
 
Data on sexual orientation, sexual history and partners will be obtained by self-report. 
Questionnaires will be administered prior to the HIV test and questions regarding recent 
sexual partners will be limited to the past 6 months in order to reduce recall bias. 
Interviewers will be trained in MSM sensitivity and in appropriate administration of 
questionnaires, to ensure an open, non-judgmental environment, to reduce social 
desirability bias in participants’ responses.  
 
3.8  Laboratory Procedures 
3.7.1  HIV Testing 
Patients will be tested using the standard procedures outlined in the National HIV 
Counselling and Testing policy [74]:   
- Following appropriate counselling, a rapid HIV test (Abbott Determine® HIV-
1/2) will be performed. 
 If the result is negative, the participant shall be considered HIV-uninfected 












 If the test is positive a confirmatory test will be performed using a second 
rapid HIV test (SD Bio-Line HIV 1/2) 
o If the second test is positive, the participant will be considered 
HIV-infected. He will receive appropriate post-test counselling. 
o If the confirmatory test is negative or indeterminate, a 2.5-5ml 
venipuncture blood draw will be performed to conduct an enzyme-
linked immunosorbent assay (ELISA) test to confirm HIV status 
 
3.7.2  CD4 T-Cell Count 
A 2.5-5ml specimen of blood will be collected in a sterile tube.  CD4 T-cell counts will be 
performed at the National Health Laboratory Services in accordance with standard 
practices. The study site will inform participants of the test results. 
 
3.7.3  Viral Diversity Assay 
The diversity testing will be performed at the Institute of Infectious Disease and 
Molecular Medicine’s virology laboratory, at the University of Cape Town. 
 
A 10 ml specimen will be collected from HIV-infected participants in an EDTA tube. Plasma 
will be extracted from the sample and stored at -70 C. Viral loads will be performed on 
these specimens when required to inform the PCR analysis.  
RNA will be extracted from plasma samples and reverse transcribed. To ensure that single 
genomes are amplified, the cDNA will be diluted to end-point. To identify infecting subtype, 
complete sequencing of the gp160 region will be performed. Env gene will be amplified 
from cDNA by nested PCR and amplicons will be directly sequenced.  
 
Studies describing HIV subtypes in different populations in South Africa in the 1990s 
utilized different subtyping techniques. Predominantly proviral HIV-1 DNA was subtyped by 
a PCR-based method, heteroduplex mobility assay (HMA), based on the V3–V5 region of 
the env gene and/or by sequence analysis of the p17 region of the gag gene [46,50]. This 
study will utilize sequencing of the gp160 env region from RNA-derived cDNA.  While 
sequencing is the most accurate approach to subtyping [75], HMA allows for more rapid 
and cheaper subtype determination. However, recombinants may be missed in the HMA 
approach [75], hence the need for confirmatory sequencing of the p17 region in the earlier 












technologies is unlikely to have significant limitations.  
 
3.7.4  Phylogenetic analysis 
Phylogenetic analysis will be conducted to assign HIV subtypes. The participants’ 
sequences will be aligned using CLUSTAL W [76], and subtypes will be assigned by 
inferring gp160 phylogenetic relatedness of participant sequences to an HIV-1 subtype 
reference set from the HIV Sequence Database [4].  Maximum Likelihood phylogenetic 
trees will be constructed from the study samples using the MEGA v5.04 software [77], 
and will include reference subtypes and CRFs from the study region [4]. A reference 
subtype tree will be constructed to visualise clustering of all the sequences. If required 
phylogenetic clusters may be confirmed by sequencing of alternate viral genes, such as 
gag p17p24. 
 
To identify inter-subtype recombinants from the env sequences sampled from the 
participants, we will use independent recombination identification programmes including: 
the Recombination Identification Program (RIP 3.0) 
(http://www.hiv.lanl.gov/content/sequence/RIP/RIP.html), REGA HIV-1 Subtyping Tool-
Version 2.0 (http://www.bioafrica.net/rega-genotype/html/subtypinghiv.html) and jumping 
profile Hidden Markov Model (jpHMM)(http://jphmm.gobics.de/) [78]. Recombinant 
viruses will be analyzed for subtype assignment and breakpoint identification by SimPlot 
software v3.5.1 (http://sray.med.som.jhmi.edu/SCRoftware). 
 
IV. Data Management 
4.1  Statistical Co siderations 
4.1.1  Sample size 
The required sample size to show a difference in subtypes between the urban and peri-
urban communities is dependent on the proportional representation of the subtypes in 
these two populations. Sample size calculations are shown below for varying proportions 
of subtype C in the two populations. All sample sizes are calculated at 90% power, 















Proportion subtype C 
in peri-urban 
population 
Proportion subtype C 
in urban population 
Sample 
size 
65% 5% 30 
65% 10% 36 
65% 20% 56 
65% 40% 180 
65% 50% 480 
75% 5% 22 
75% 10% 26 
75% 20% 38 
75% 40% 92 
75% 50% 170 
90% 5% 14 
90% 10% 18 
90% 20% 22 
90% 40% 42 
90% 50% 40 
 
Based on relatively conservative estimates of 75% and 50% representation of subtype C 
in the peri-urban and urban respectively, a total sample size of 170 (85 from each 
geographical population) is required. Allowing for loss of specimens due to difficulties in 
amplification of cDNA or indeterminate sequencing results, a total sample size of 200 
HIV-infected participa ts will be recruited (100 from each geographical population).   
 
4.1.2  Data Analysis 
Data analysis will be performed in the statistical programme STATA (Stata Corp. LP, 
College Station, TX, United States of America).  Descriptive statistics will be employed 
for basic characterization of both predictor and outcome variables.  Bivariate 
comparisons (using Student’s t-test, Wilcoxon rank-sum, chi-squared and Fisher exact 
tests as appropriate) will be used to identify basic associations. Multivariate logistical 
regression models will be developed to examine the possible associations between with 













4.2  Data Management  
The study coordinator and study nurse will review all data sheets and questionnaires for 
completeness and legibility. Study staff will ensure that standard operating procedures 
for Good Clinical Practice (GCP) are adhered to. Study data will be entered into a 
Microsoft Excel database designed for this study. Data entry will be performed by a 
trained staff member, and 15% of data entry will be checked for quality control purposes.   
The site investigator will make study documents readily available for inspection by the 
local Research Ethics Committee for confirmation of the study data and procedures. 
 
Study files will be kept at the study site. Study files will be stored by the site staff in a 
locked cupboard, and signed consent forms will be kept separate from questionnaires 
and laboratory test results. Access will be restricted to study personnel authorized to 
handle research documents and site monitors. 
 
V. Ethical Considerations 
The study protocol and all study procedures will be implemented in accordance with 
national GCP standards [79] and the Declaration of Helsinki 2008 [80]. 
 
The study protocol and all study instruments will be reviewed by the Faculty of Health 
Sciences’ Human Research Ethics Committee (HREC) of the University of Cape Town 
(UCT). 
 
5.1  Consent Procedures 
Eligible subjects will be identified by the process outlined in Section II:6. Trained 
research staff will explain the study objectives and procedures to all potential 
participants, including possible risks associated with participation, and the right to refuse 
study participation or to withdraw. Participants will receive the informed consent form to 
read and consider. Any issues will be discussed and all questions about the study will be 
answered. Written informed consent will be sought from all study participants, in their 
home language. Before signing the consent form, all participants will be questioned for 
comprehension of the consent form and study. 
 
The informed consent form will explain: 












 What is involved in participating, including the number and duration of clinic visits 
 The risk and benefits of participation 
 That all information provided will be treated as confidential and will not be stored 
with participants’ names 
 The voluntary nature of participation 
o The participant’s right to decide not to participate, to refuse to answer any 
question, or to withdrawal from the study at any time without 
consequence. 
 
The informed consent form will be translated into Xhosa (local African language) and 
Afrikaans, and back translated into English to verify content. 
 
Participants must be self-identified MSM, and given the sensitive nature of this 
disclosure, we will apply to the ethics committee for a waiver of parental consent in 
participants less than 18 years of age. We believe this is an acceptable request, as the 
research has no more than minimal risk and requiring adult consent may preclude some 
individuals from participation if they have not disclosed their sexual preferences to their 
parents, thus potentially introducing a selection bias. 
  
5.2  Participation Risks and Benefits 
There is a slight risk associated with venipuncture for the laboratory tests.  Participants 
will probably experience pain and may experience some bruising at the venipuncture 
site.  Very rarely, a participant may develop an infection at the venipuncture site.  All of 
these potential medical risks will be addressed appropriately at the clinic site.   
Participants may also become embarrassed, worried, or anxious when receiving HIV 
counselling and testing.   
Participants will experience emotional distress if diagnosed as HIV-infected. Counsellors 
who have received training in MSM-appropriate counselling and who have extensive 
experience in HIV education and counselling, will be available on site.  These 
counsellors will provide the pre- and post-test counselling for the study.  All HIV-infected 
participants will be referred to the closest HIV care clinic or to an appropriate MSM-
friendly clinic of their choice. 
There is a small risk of loss of confidentiality, however all reasonable efforts will be made 












Participants will benefit from study participation by learning their HIV status and 
receiving risk-reduction counselling. Participants who test HIV-infected will receive their 
CD4 T-cell count as well as appropriate medical referrals.   
 
5.3  Protection of Confidentiality 
Each participant will be assigned a unique study number and all questionnaires, 
laboratory specimens and laboratory data will be identified by this number, not by 
participant name. The participant’s number will also be used in the database to further 
ensure confidentiality. All study documentation, including informed consent forms, 
demographic information, questionnaires and laboratory results will be kept in a locked 
cupboard.  Access will be restricted to study personnel authorized to handle research 
documents, sponsor or UCT HREC representatives and site monitors. 
No individual identifying information will be disclosed in reports, publications, or 
presentations. 
 
5.4  Reporting of Adverse events 
No drug or other medical intervention is being administered in this study and thus no 
experimental product-related adverse events are anticipated.  The researchers will 
record any reported social harms occurring as a result of participation in the study. All 
adverse events will be reported to the Faculty of Health Sciences’ HREC in accordance 
with GCP guidelines [79]. 
 
5.5  Remuneration 
Participants will receive R100 as reimbursement for their time and transport costs. 
 
VI. Communications  
6.1  Stakeholders  
MSM communities are well represented in South Africa, and particularly in Cape Town 
which is known as Africa’s “Pink City”.  Several active LGBT advocacy and research 
groups, as well as groups providing clinical services to LGBT, exist in Cape Town 
making it an ideal site in which to conduct HIV research among MSM.  The researchers 
will inform these groups of the study and request assistance with recruitment (where 












Other important stakeholders include City Department of Health, the Provincial Health 
Authorities, as well as fellow researchers in the field of HIV and MSM. 
 
6.2  Reporting and implementation plan   
The DTHF has built a good partnership with the MSM community in Cape Town. The 
Foundation has established weekly or biweekly community meetings within five township 
communities in greater Cape Town. This programme provides safe spaces for MSM to 
meet and engage in educational, social, and research activities. These spaces also 
provide access to hard to reach MSM and offer opportunities to solicit feedback directly 
from the MSM community with regards to new or on-going research activities. This 
protocol will be discussed in these forums prior to implementation and the study findings 
will be presented to these groups in a language-appropriate document and presentation.  
 
The DTHF also has an excellent relationship with the City Department of Health and the 
Provincial Health Authorities. We will engage with the health authorities regarding the 
possible implications of research findings to influence public health policy in this area.  
 
Results will also be submitted to relevant local and international conferences, to increase 
dissemination of information. A manuscript will be submitted to a peer-review journal and 
all journal publications would be registered on PubMed Central. 
 
VII. Logistics 
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The focus of this literature review is to provide a brief overview of the current HIV 
epidemic, to review the concept of HIV subtypes and to describe the distribution of HIV-1 
subtypes in South Africa. In addition, the literature review will describe the at-risk group 
of men who have sex with men and review the current knowledge of HIV-1 subtypes 
among MSM in Africa. A formal structured review will be used to describe HIV-1 
subtypes both in South Africa and among MSM in Africa, as this is the key subject of this 
thesis and no recent published reviews on the topic are available. 
 
I. HIV epidemiology 
In the early 1980s doctors in Eastern and Central Africa were facing a surge of patients 
with severe wasting and opportunistic infections, locally named “slim disease” [1], while 
in America increasing reports of unexplained cases of Pneumocystis carinii pneumonia 
and Kaposi’s sarcoma were emerging from hospitals in Los Angeles [2,3].  However, the 
connection between these two new epidemics was only recognized after the aetiological 
agent of the CDC-named “Acquired Immune Deficiency Syndrome” (AIDS) [4] was 
isolated in 1983 [5], and the first confirmed case of Human Immunodeficiency Virus 
(HIV) infection was identified in a stored sample, collected in the Congo in 1959 [6].  
 
Despite international efforts to understand and halt the spread of this disease, HIV has 
subsequently resulted in one of the largest pandemics known to mankind. In 2010 34 
million people were estimated to be living with HIV globally, with 2.7 million new 
infections and 1.8 million AIDS-related deaths occurring in the same year [7]. 
 
Sub-Saharan Africa remains the most heavily affected region. Two thirds of all HIV-
infected people live in sub-Saharan Africa, 70% of new infections in 2010 occurred in 
this region and it is estimated that 1.2 million sub-Saharan Africans died from AIDS in 
2010 [7].  However there is some hope in the midst of this devastation: sub-Saharan 
Africa boasts the largest scale-up of ART access, with 49% coverage being achieved by 
2010 [7], and as a result, over the past five years there has been a decreasing trend in 
both HIV-related mortality and incident infections. 
 
II. HIV Subtypes 
HIV is a retrovirus, belonging to the genus Lentivirus, and is divided into two strains: HIV 












virus (SIV) from chimpanzees (Pan troglodytes troglydytes) [8], occurring in the 1930s 
[9]. Similarly, HIV-2 is thought to originate from SIV found in sooty mangabey monkeys 
(Cercocebus atys atys) [10], in the 1940s [11]. 
 
The global pandemic is comprised predominantly of HIV-1 infections, while HIV-2 is 
largely restricted to West Africa [12,13]. Since its zoonotic transmission to humans, HIV-
1 has diversified extensively due to the high rates of viral replication, high frequency of 
reverse transcriptase errors [14] and recombination, the large pool of infected individuals 
and prolonged period of infection [15]. Based on this diversity, HIV-1 is further classified 
into three distinct lineages: Groups M, N and O [16].  Groups N and O are relatively rare, 
and are largely confined to central Africa and Cameroon [17,18]. HIV-1 Group M is the 
dominant virus globally, and is further classified into a number of subtypes or clades 
[16,19]. To date nine subtypes of group M have been identified: A-D, F-H, J and K [20]. 
In addition to these subtypes, there are also recombinant viruses, that is novel viruses 
arising when “co-infecting viruses exchange genetic information” [21]. Recombinant 
viruses that are epidemic strains are called circulating recombinant forms (CRFs) [22], of 
which approximately 52 have been identified [20].  
 
2.1  Geographic Distribution of Subtypes 
The high degree of genetic diversity of HIV-1 has enabled scientists to study and monitor 
spread of the virus around the globe. Central Africa has the greatest diversity of HIV-1 
subtypes and the highest representation of recombinant viruses [15,23], as one would 
expect at the source of the pandemic. The global distribution of HIV-1 subtypes and 
recombinant viruses is summarized in Figure 1. 
 
The most prevalent subtypes globally are A, B, C and the recombinant virus CFR02_AG 
[15]. Subtype A occurs predominantly in Central and East Africa, Eastern Europe and in 
Central Asia. CFR02_AG is concentrated in West Africa and parts of Central Africa. 
Subtype B is one of the most widely spread subtypes, and is the dominant virus in the 
Americas, West and Central Europe and Australia. It is also common in Asia, North 
Africa and the Middle East. Of interest is that subtype B is rare in sub-Saharan Africa 
[15,24]. Subtype C is the most prevalent subtype in China, India and East and southern 
Africa [20], most notably in Zimbabwe [25], Malawi [26], Mozambique [27] and South 













Figure 1: Global distribution of HIV-1 subtypes (from Hemelaar et al, 2011 [24]) 
 
III. Review of HIV-1 Subtypes in South Africa 
A structured literature review was performed in order to describe HIV-1 subtypes 
identified among infected patients in South Africa, from the 1980s to date.  
 
3.1  Methods 
Included in the review were all epidemiological studies that described the HIV-1 subtype 
distribution within a South African-based cohort. Samples could be derived from 
community or clinic based studies, antenatal surveys or from sample banks, such as 
blood bank specimens.  
 
The following studies were excluded: a) studies of selected strains performed to assess 
different HIV subtyping methodologies, to investigate specific phenotypic, genotypic, 
disease or immune response characteristics, or to investigate phenotypic or genotypic 
differences between strains; b) studies of non-South African based cohorts, or cohorts 












There were no exclusions based on participant age, sexual orientation, method of HIV 
acquisition or subtyping methodology.  
 
The PubMed and Africa-Wide Information electronic databases were searched. The 
following search terms were used in the PubMed search: (“HIV-1/classification” [MeSH 
term] OR “HIV-1/genetics” [MeSH term] OR “Phylogeny” [MeSH term]) AND (“subtype” 
OR “clade”) AND “South Africa”. A filter for “human” studies was added. For the Africa-
Wide Information database, the following search terms were used: [HIV-1 classification 
OR HIV-1 genetics] AND HIV subtype AND “South Africa”. The Africa-Wide Information 
search was restricted to peer-reviewed journals. Titles and abstracts identified by the 
search terms were screened for inclusion/exclusion criteria. Full paper review was 
performed on the remaining papers, and the reference lists were reviewed for additional 
papers.  
An electronic data extraction form was developed and relevant data from the selected 
studies were captured on this form. Where possible, authors were contacted to clarify 
information.  
 
3.2  Results 
3.2.1  Identification of studies 
The electronic database searches were performed on 09 June 2013. The PubMed 
yielded 196 results. Title and abstract review excluded 175 papers. Full review of the 
remaining 21 papers resulted in the exclusion of two studies in which specific strains had 
been selected for the analysis.  
The Africa-Wide Information database search yielded 106 results, of which all but one 
were excluded on title and abstract review as ineligible or duplicates of the PubMed 
search. The additional paper was included in the structured review, following full paper 
review. Review of paper references yielded a further two papers that had been missed 
by the electronic search. Therefore the final literature review was performed on 22 
studies (Table 1).  
 
3.2.2  Overview of studies  
3.2.2.1  Study Populations 
The 22 studies spanned nearly two and a half decades, with specimens collected from 












studies involving patients from the Western Cape, all of which were based in Cape 
Town. The majority of the studies did not report on participant nationalities, but two 
specifically noted that all the participants were South African [30,31].  Two studies 
included participants from outside of South Africa, and reported on the representation of 
South African participants [32,33], and Romani et al noted that only one participant in 
their study was from a country other than South Africa [34].  
 
Populations sampled were predominantly patients from the South African public health 
sector, including patients identified as HIV-positive at VCT clinics (two studies), HIV care 
clinics and hospitals (nine studies), antiretroviral treatment clinics (four studies) and 
antenatal clinics (three studies). Less frequently sampled populations were patients from 
private hospitals (three studies), Western Province Blood Transfusion service donors 
(two studies), members of an HIV support group (one study), miners (one study), and 
participants from a cohort of sex workers (two studies) and of HIV-positive patients (one 
study). Some studies obtained samples from more than one patient source.  
 
3.2.2.2  Study Designs 
All 22 studies were cross-sectional surveys.  
 
3.2.2.3  Sampling 
Sampling methods were poorly described and eight studies did not report sampling 
methodology at all. Sampling methodology entailed attempted recruitment of all eligible 
clients testing HIV-positive at VCT (two studies), attending an HIV Wellness clinic (one 
study), initiating ARV treatment (one study), participating in an antenatal survey (one 
study), enrolled in an HIV positive cohort (one study) or presenting at study clinics (one 
study) during the study periods. No data were provided on the proportion of patients that 
declined study participation. Convenience sampling was utilized in at least two studies. 
Becker et al utilized specimens selected based on patients’ race, gender and sexual 
orientation [33], van Harmelen et al (1997) selected specimens based on likely mode of 
HIV transmission [35] and Bredell et al selected participants based on proportional 
representation of nationalities working in the mines [32]. 
Naidoo et al and Papathanasopoulos et al were the only studies in which specimens 














Sample sizes ranged from 13 to 320 participants, with an average of 98 participants per 
study.  
 
3.2.2.4  Demographics 
Participant race was not reported in 12 studies. In two studies 100% of participants were 
black Africans, and in six other studies black Africans comprised the majority of 
participants (36%-97%). In only one study were the majority of participants (78%) white 
South Africans. Six studies included coloured participants with their proportional 
representation ranging from 5% to 31%.  
 
Gender distribution of participants was not reported in five studies. Two studies were 
performed exclusively in females, and two studies exclusively in men. Two studies were 
comprised of majority male participants, and in the remaining 11 studies, women 
comprised the majority of participants (52%-90%).  
 
Overall 15 studies included men, of which five did not report on sexual orientation. One 
study comprised 100% heterosexual individuals [31], a second study included 99% 
heterosexuals and 1% of participants who acquired HIV infection through mother to child 
transmission (MTCT) [37], and a third reported 97% heterosexual and the remaining 3% 
unknown [38]. The remaining seven studies included heterosexual, bisexual and 
homosexual participants. An eighth study did not report gender distribution, but did 
report sexual orientation. Among these eight studies, Jacobs et al (2008) reported a mix 
of heterosexual, homosexual and bisexual individuals and MTCT-infected individuals, 
but did not report their proportional representation [39].  Engelbrecht et al (1995) 
reported 50% homosexual participants and 21% bisexuals [40]; and in the remaining six 
studies MSM orientation accounted for 3%-43% of participants.  
 
3.2.2.5  HIV Infection 
None of the reviewed studies were able to report when participants acquired their HIV-
infection. However, Nwobegahay et al reported that all participants in a 2008 study were 
likely to have been infected after 1999 [41], and Iweriebor reported that none of the 
participants in their study were likely to have been recently infected (in the past six 












attempted to obtain specimens from recently infected women by restricting eligibility to 
women in their first pregnancy [42]. 
 
3.2.2.6  HIV-1 Subtypes 
Two studies included non-South Africans but provided data by nationality, for these 
studies only the data from South Africans were included. Therefore, in total, 2158 
participants were enrolled in the 22 studies.  
Overall, 94% (95% Confidence interval [CI]: 93-95%) of participants were infected with 
subtype C virus, but the proportions varied across studies, predominantly influenced by 
when samples were collected, and from which population groups. Studies in which 
samples were collected in 1990s (five studies in total) tended to have a wider range of 
population groups, with heterosexual and MSM participants enrolled and greater 
variation in the proportion of infections attributed to subtype C [33,35,40].  Studies 
performed from 2002 onwards (12 studies) sampled largely from the general population. 
Only two of these studies reported on participants’ sexual orientation and in both studies 
heterosexual participants accounted for >90% of the sample [34,43]. All but one of these 
12 studies reported ≥94% subtype C virus, with five studies reporting 100% subtype C 
virus [36,37,42,44,45]. 
 
Overall, subtype B virus accounted for 4% (95% CI: 3-5%) of South African HIV 
infections, but the contributing proportion of subtype B decreased from ±50% in some 
earlier studies [35,40] to less than 4% in later studies with general population samples. 
Subtype B was found in predominantly MSM participants, with only four studies reporting 
subtype B virus in heterosexual participants, and always in low prevalence. 
 
Other subtypes reported included subtype D (reported in early studies [35,40]), subtype 
A (1% of all participants), and occasional reports of subtypes F1, G, J, U,  and CRF_AG, 
DC, BC, AB, A1/C, CJ and CH recombinants. 
 
Further details on subtypes among MSM are reported in the literature review of HIV-1 
















3.3  Limitations 
Only English language papers were included in this review, and as such studies reported 
in French from Francophone African countries may have been missed.  
 
All these studies were cross-sectional surveys and as such described the HIV-1 
subtypes among prevalent, rather than incident HIV-1 cases (length-bias sampling). This 
may hamper our understanding of currently circulating HIV-1 strains.   
 
The heavy reliance on non-random, convenience sampling of populations may have 
resulted in considerable selection bias in these data. Furthermore, as data are largely 
restricted to those patients utilizing public health services, and those who were prepared 
to provide blood samples for research purposes, the generalizability of these data may 
be limited. 
 
Furthermore, paucity of data on nationality of participants gives rise to difficulties in 
interpreting the presence of rare strains, which may have been detected in immigrants or 
refugees, or introduced into the South African epidemic through international travel. 
Similarly, the limited data on HIV transmission routes restricts our ability to determine the 
trend of strains in the different at-risk population sub-groups  
 
3.4  Discussion 
The dominant HIV-1 virus in South Africa is subtype C. Studies in largely black African, 
heterosexual populations show an overwhelming subtype C epidemic, and despite some 
evidence of increased viral diversity this finding remained consistent across the review 
period.  Genotyping studies have shown that the South African HIV-1 C epidemic most 
likely resulted from multiple introductions of this subtype into the general population 
[35,46].  Subtype C is the most prevalent subtype in southern Africa [20] and likely 
spread to South Africa via regional travel [33,35,47], particularly through mobile groups 
such as migrant workers [48-50], immigrants [47], refugees [47], and truck drivers 
[33,51]. This spread was facilitated by urbanisation [52] and well established 













In contrast, studies including MSM in South Africa reported largely subtype B virus in this 
population group. These early subtype B infections were associated with travel history to 
the United States of America, Europe, Australia and Thailand [35,54], regions in which 
this subtype was and remains the dominant virus [20]. 
 
 
IV. Men who have sex with men 
The phenomenon of men-who-have-sex-with-men (MSM) includes any male who 
engages in sexual activity with another male, including men who identify as homosexual, 
bisexual or heterosexual. 
 
MSM are a high risk group for HIV acquisition. This is due, in part, to biology risk factors, 
with unprotected receptive anal intercourse carrying the highest sexual intercourse-
related risk [55-57], as well as prevalent behavioural risk factors including multiple 
partners [58] and low use of condoms and appropriate lubricant [57,59]. In addition there 
are social constructs that may place MSM at a higher risk for HIV infection. In many 
African countries MSM activity is criminalized, driving this population underground, and 
restricting access to adequate health care and HIV preventative services. Even in 
countries in which MSM activity is legal, such as South Africa, stigma, social prejudice 
and human rights abuses are all too common [60].   
 
Consequently, HIV prevalence in MSM groups is consistently higher than in general 
population epidemics [57,61]. A systematic review and meta-analysis of HIV prevalence 
in MSM compared to background populations reported that MSM have 11 times the 
odds of HIV infection in countries with generalised epidemics, and nearly four times the 
risk in African countries [61].  Similarly, the HIV prevalence among South African MSM 
has consistently been reported as higher than that of the overall age-matched, male 
population. The generalised HIV prevalence in South Africa is estimated to be 18% [62], 
compared to prevalence among MSM ranging from 13 to 44% [59,63,64] in different 
cities. In addition MSM who self-identified as “gay” or “homosexual” had a higher risk of 
HIV infection compared to those who identified as “bisexual” [64,65]. One study reported 
that HIV prevalence in bisexual and straight men was the same as the background 













There is strong behavioural evidence of bridging between MSM and heterosexual 
populations. A study conducted in Botswana, Malawi, and Namibia reported high levels 
of female sexual partners among self-identified MSM. While 38% of participants 
described their sexual orientation as “bisexual”, 54% reported female sexual partners in 
preceding 6 months. Overall, 17% of participants reported ongoing concurrent 
relationships with a man and a woman [60]. Similarly, 18% of MSM in Senegal reported 
recent intercourse with a female partner [58], and in Kenya 12% of MSM surveyed were 
married, and 60% reported sex with both male and female partners [57]. 
 
The findings from South African studies have been consistent with those in other African 
countries, with 9-30% of self-identified MSM surveyed describing their sexual orientation 
as “bisexual”  [59,63,65] and in one study as many as 32% identified as “straight” [63]. In 
a Cape Town based study, 1% of MSM participants identified as heterosexual, but 8% 
reported that they were married [59]. Across these South African studies 36% of self-
identified MSM reported a past history of vaginal sex [64], 63% reported regular 
partnerships with women  [63] and up to 6% in a Cape Town township study reported a 
current female sexual partner  [59]. However, in South Africa, there are no data on the 
impact of these behavioural links on the MSM and generalised HIV epidemics. 
 
V. HIV-1 Subtypes among MSM in Africa 
A structured literature review was performed in order to describe HIV-1 subtypes 
identified among men who have sex with men, in Africa from the 1980s to date.  
 
5.1  Methods 
Included in the review were all epidemiological studies that described the HIV-1 subtype 
distribution within an African MSM cohort. Samples could be derived from country, 
community or clinic based studies, or from sample banks, such as blood bank 
specimens.  
 
Studies of selected strains and review articles were excluded from the literature review.  
There were no exclusions based on participant age or subtyping methodology. 
 
The PubMed and Africa-Wide Information electronic databases were searched. The 












term] OR “HIV-1/genetics” [MeSH term] OR “Phylogeny” [MeSH term]) AND 
(“homosexuality” [MeSH term] OR “homosexuality, male” [MeSH term]) AND (subtype 
OR clade) AND Africa. A filter for “human” studies was added. For the Africa-Wide 
Information database, the following search terms were used: [HIV-1 classification OR 
HIV-1 genetics] AND “homosexuality, male” AND “South Africa”. Titles and abstracts 
identified by the search terms were screened for inclusion/exclusion criteria. Full paper 
review was performed on the remaining papers, and the reference lists were reviewed 
for additional papers.  
An electronic data extraction form was developed and relevant data from the selected 
studies were captured on this form. Where possible, authors were contacted to clarify 
information.  
 
5.2  Results 
5.2.1  Identification of studies 
The electronic database searches were performed on 10 June 2013. The PubMed 
yielded 8 results. Title and abstract review excluded five papers. Full review of the 
remaining three papers confirmed their eligibility.  
The Africa-Wide Information database search yielded three results, one of which was 
excluded as a duplicate of the PubMed search results and two were deemed ineligible 
based on title and abstract review. No additional studies were identified via review of the 
papers’ references.  
 
In addition, three studies from the South African review reported HIV-1 subtypes by 
sexual orientation (including MSM) were not identified in the electronic search, but were 
included in the structured review.  
Therefore the final literature review was performed on six studies (Table 2).  
 
5.2.2  Overview of studies:  
5.2.2.1  Study Populations 
Four of the six studies occurred in South Africa. These four studies predominantly 
recruited patients from public healthcare services in Cape Town over a period ranging 
from 1984 to 2004. One study was performed among urban MSM in Senegal in 2004 
and the sixth study reported on HIV-1 subtypes among MSM in and around a large city 












5.2.2.2  Study Designs 
Five of the studies were cross-sectional surveys. However, Tovanabutra et al reported 
on patients from an HIV incident cohort study: 43% of specimens were prevalent HIV 
infections identified at study baseline, and 57% were incident HIV-1 infections that 
occurred during the study period [66]. 
 
5.2.2.3  Sampling 
A range of sampling methodologies were used across these studies: two studies did not 
report on sampling methodology, one study utilized a convenience sample of specimens 
available from South African public health care clinics, one study selected participants 
based on likely mode of HIV transmission, another study utilized snowball recruitment (a 
technique used to recruit hard to reach populations), and the final study utilized a 
combination of convenience sampling of prevalent cases and incident cases occurring in 
the study cohort.  Sample sizes ranged from 14 to 107 across these six studies. 
 
5.2.2.4  Demographics 
One South African study did not report on participants’ gender, although 97% of that 
study sample was reportedly heterosexual [28]. One South African study and the 
Senegalese study were performed in exclusively male participants, while the male 
representation in the remaining three studies ranged from 45% to 67%. 
 
Ndiaye et al recruited exclusively MSM [67], while MSM accounted for 3-71% of study 
participants in the remaining studies. In the Kenyan study, 39% of participants were 
female sex workers [66]. 
 
Racial characteristics of participants were not reported in three of the studies. The three 
studies that did report on race were all South African based. In the South African study 
performed exclusively in MSM men, all 14 participants were white men. In the remaining 
two South African studies [34,35], MSM were predominantly white (54% and 66% 
respectively), while the heterosexual participants were predominantly black (62% and 
















5.2.2.5  HIV-1 Subtypes 
Across the four South African studies, 78% (95% CI: 64-89%) of MSM participants were 
infected with HIV-1 subtype B virus, compared to 5% (95% CI: 3-9%) of the heterosexual 
patients in the same surveys (p<0.001); 9% (95% CI: 2-21%) of MSM were infected with 
subtype C, compared to 92% (95% CI: 87-96%) of the heterosexual participants 
(p<0.001). In addition, 13% of MSM were infected with subtype D virus. 
In the two studies that reported subtype by both race and sexual orientation, only two 
one black African MSM were included, one of which had an HIV-1 subtype C infection 
and the other subtype B [34,40]. 
 
Ndiaye et al reported that 40% of the Senegal study’s MSM participants were infected 
with subtype C, 24% with recombinant CRF02_AG, 19% with subtype B, and the 
remaining 8% with additional recombinant viruses. They noted that these subtypes were 
similar to those occurring in the country’s general population and female sex workers, 
although in different proportions: over 50% of infections in Senegal’s general population 
and female sex workers are attributed to CRF02_AG virus, and <6% due to subtype C or 
B [67]. 
 
Tovanabutra et al noted that HIV-1subtype A accounted for 62% of HIV infections 
among MSM participants in the Kenyan study, and 80% of the infections among female 
sex workers and heterosexual participants. The remaining infections in both groups were 
due to a variety of recombinant viruses. The authors note that a high proportion of 
recombinant viruses were noted in the incident infections versus prevalent infections 
[66]. 
 
5.3  Limitations 
Only English language papers were included in this review, and as such studies reported 
in French from Francophone African countries may have been missed.  
 
The majority of these studies were cross-sectional surveys and therefore likely reported 
on prevalent HIV infections. This may limit our ability to extrapolate these findings to the 
currently circulating HIV-1 subtypes, as illustrated by the increased representation of 













The South African MSM data are largely restricted to white patients and thus the 
generalizability of these data to the wider MSM population may be limited.  
 
5.4  Discussion 
The South African studies reported a predominance of subtype B virus among MSM and 
the findings suggest that the MSM epidemic is independent of the generalized 
heterosexual epidemic [35].  However, three of these studies were performed early in 
the South African HIV epidemic (prior to 2000) and in predominantly white MSM. Across 
all four studies only one known black African MSM was enrolled. Therefore there 
remains a dearth of current data on HIV-1 subtypes among South African MSM, and 
particularly among black African men.  
 
The 1999 van Harmelen study reported no subtype B viruses detected among Cape 
Town heterosexuals, but also noted the first subtype C virus identified in a South African 
MSM [28]. As already noted, there is substantial behavioural data to support the concept 
of bridging between MSM and general populations in South Africa [59,63-65], and this 
phenomenon could impact the evolution of the HIV-1 epidemics in these population 
groups.  
 
The Senegalese study also reported “bridging” behaviours across population groups: 
56% of the study participants reported a regular female partner, with 82% reporting any 
heterosexual contacts. The HIV-1 subtypes identified in the MSM population were the 
same as those noted in the general population, and this may suggest linking of the HIV 
epidemics between the groups. However, the authors noted that the prevalence of the 
subtypes were very different in the different groups. As this was a cross-sectional study 
and the first of its kind in Senegal it is not possible to determine if the HIV-1 subtype 
proportions in these populations are in fact changing over time – and if so, whether that 
change is one of diversification or convergence. Similarly, in the Kenyan study 60% of 
the overall MSM cohort reported sex with a female partner [57], and 46% of the 
participants with genotype data available. However, in this study the distribution of 
subtypes were very similar among the MSM and FSW groups, suggesting that these HIV 













Of interest is that in the Kenyan studies, recombinant viruses were over-represented in 
the incident cases, compared to prevalent cases. It is therefore possible that 
recombination of different subtypes prevalent in different population groups may be 
indicative of recent bridging across epidemics [66].  
   
VI. Summary  
While there are considerable data available on HIV-1 subtypes among the general South 
African population, there are few current data on HIV-1 subtypes among South African 
MSM. In addition, while there are numerous reports of behavioural links between the 
MSM and general populations in the country, there are no recent molecular 
epidemiological data assessing the impact of these behaviours on the previously 
independent epidemics in these two population groups. 
 
The South African government has identified MSM as a key population for targeted 
interventions in the current National Strategic Plan on HIV, STIs and TB [68]. In order to 
plan and implement effective strategies an improved understanding of HIV-1 epidemic 
among MSM is required. Furthermore, insights into the possible interactions or bridging 
between different population groups and previously independent epidemics, may 
increase our understanding of the drivers of our local epidemic, and further inform local 












Table 1: Summary of structured literature review of HIV-1 subtypes in South Africa 
 Author, publication 
year 
Sampling 


















hospital in Cape 
Town 
Not reported 14 
7% black African                    
14% coloured                    
78% white 
100% male 
50% homosexual                           
21% bisexual                                   
21% heterosexual                       
7% blood 
transfusion 
B: 50%                     
D:36%                       
C:14%                     
Homosexual:                         
D:57%; B:43% 
Bisexual:                         
B: 66%; D: 
33%                               
Heterosexual:                           
C:66%; B:33%    











participants:    
63% black African                    




13% female                     
13% not 
specified  
Only reported for 1 
SA participant:  
1 MSM 
Overall: 
C: 83%                    
B: 8%                      
D: 8%                          
SA participants:    
C: 88%                    
B: 13% 
MSM: B  








mode of HIV 
transmission 
61 
36% black African                                  
33% white                    
31% coloured                     
Heterosexual: 
48% female 
48% heterosexual                   
39% homosexual                      
3% bisexual                       
5% MTCT                          
2% blood 
transfusion                 
3% unknown 
B: 52%                          
C: 43%                      
D: 3%                        
E: 1.5% 
Heterosexual/ 
Vertical:                      
C:81%; B:13%         
MSM:                         
B: 96%; D: 4% 
4 Bredell [32], 1998 Not reported Gauteng 
Migrant mine 
workers from 








43 Not reported 100% male Not reported C: 100%  Not reported 




Not reported 72 Not reported 100% female Not reported 
C: 97%                         
A: 1.5%                          
B: 1.5% 
Not reported 














107 Not reported Not reported 
97% heterosexual                            
1% homosexual                         
2% bisexual 
C: 92%                           
B: 7%                               
A: 2%     
Heterosexual:                         
C:93%; B: 5%; 
A: 2%    
Homosexual:                         
B: 100%                         


























Not reported 81 Not reported 
62% female   
6% not 
reported 
Only reported for 
WC:       
84% heterosexual          
4% MSM                         
12% unknown 
C: 94%                           
B: 4%                               
BC recombinant: 
     1%                                  
AB recombinant: 
      1%                        
Not reported 
by orientation 










60 Not reported Not reported Not reported 
C: 77%                         
B: 17%                             
A: 3%                                 
G: 1.5%                        
DC recombinant: 
     1.5% 
Not reported 





Not reported 42 Not reported 79% female 100% heterosexual C: 100% Not reported by orientation 











127 Not reported 87% female Not reported 








private or public 
hospitals/clinic 







Not reported 140 
82% black African                    
14% coloured                        
4% white 
66% female 









C: 95%                         
B: 4%                      














































115 94% black African                    6% not reported 52% female 
97% heterosexual                     
3% not reported 
C: 97%                                 
A: 1%                                    
B: 1%                                     
C/J recombinant:  
     1% 
Not reported 
by orientation 




private or public 
hospitals/clinic 







Not reported 320 
64% black African                    
31% coloured                    
5% white 
66% female 
91% heterosexual            
4% MSM              
3% MTCT                         
2% unknown 
C: 89%                      
B: 7%                            
A: 3%                    
F1: 0.3%                     
U: 0.3%                      
G: 0.3%                      
CH recombinant: 





MSM were B 
(all white and 
coloured) 





Not reported 58 
91% black African                    
5% coloured                    
3% white 
55% female 
93% heterosexual                             
5% MSM                                  
2% unknown        
C: 93%                      
B: 7% 
MSM:  
B:66%; C:33%              
Heterosexual: 
C: 96% 














83 Not reported 
65% female                     
4% not 
reported 
Not reported C: 100% Not reported 











390 Not reported Not reported Not reported C: 100%  Not reported 









32 Not reported 75% female                Not reported 
C: 94%                        
A1/C 
recombinants: 
     6% 
Not reported 













* Percentages in cells may not sum to 100%, due to rounding up. 
Note: ARV = Antiretroviral; ANC = Antenatal clinic; VCT = Voluntary Counselling and HIV Testing; SA = South Africa; MTCT = 
Mother to child transmission; WC = Western Cape  

















57 100% black African Not reported Not reported 
C: 98%                       
BC recombinant: 
     2%  
Not reported 














VCT clinic  
54 100% black African 
73% female                    
1% not 
reported         
Not reported 
C: 96%                       
B: 2%                       
J: 2% 
Not reported 







Not reported 123 Not reported Not reported Not reported C: 100% Not reported 

























Table 2: Summary of structured literature review of HIV-1 subtypes among MSM in Africa 
 
 Author, publication year 
Sampling 









1 Engelbrecht [40], 1995  1984-1992 South Africa 
HIV-infected patients 
attending public 
hospital in Cape Town 
Not reported 14 
Homosexual: 
100% white           
Bisexual:       
100% white 
100% male 
50% homosexual                                           
21% bisexual                                   
21% heterosexual                       
7% unknown 
Homosexual:                                             
43% B; 57% D                        
Bisexual:                                    
66% B; 33% D                               
Heterosexual:                               
66% C; 33% B                 
2 van Harmelen [35], 1997 1993-1994 South Africa 
HIV-infected patients 
attending public 
hospitals in Cape 
Town 
Selected based 
on mode of HIV 
transmission 
61 
Homosexual:                        
58% white                   
42% coloured    
Bisexual:                     
100% white                
Heterosexual:                     
62% black 
African            
28% coloured              
10% white 
67% male 
48% heterosexual                   
39% homosexual                      
3% bisexual                                        
10% unknown  
Heterosexual/Vertical:                      
81% C; 13% B                      
MSM:                               
96% B; 4% D 
3 van Harmelen [28], 1999 1994-1996 South Africa 
HIV-infected 
individuals attending 





107 Not reported Not reported 
97% heterosexual                            
1% homosexual                                    
2% bisexual 
Heterosexual:                         
93% C; 5% B; 2% A             
Homosexual:                                           
100% B                                            
Bisexual:                                       
50% C; 50% B 
4 Romani [34],  2009 2002-2004 South Africa 
HIV-infected patients 
from Cape Town 
Metropole 
Not reported 58 
MSM:                        
66% white                   
33% black    
Heterosexual:                     
96% black 
African            
4% coloured        
45% male 
93% heterosexual                             
5% MSM                                 
2% unknown        
MSM: 66% B; 33% C              
Heterosexual: 96% C 
5 Ndiaye [67],   2009 2004 Senegal Urban MSM 
Snowball 
technique 70 Not reported 100% male 100% MSM 
C: 40%                              
CRF02_AG: 24%                   
B: 19%                                     














6 Tovanabutra [66], 2010 2005-2006 Kenya 
Prospective Incidence 
Cohort study among 
MSM and FSW in and 
around Mombasa 
All sero-




23 Not reported 61% male 
57% MSM                            
39% FSW                             
4% heterosexual 
MSM:                                  
A: 62%                                   
AA2CD: 15%                                     
AD recombinant: 8%                                      
AC recombinant: 8%                                    
DG recombinant: 8%                      
FSW & heterosexual:                                  
A: 88%                                   
AA2D: 11%                                     
AD recombinant: 11%                     
 
* Percentages in cells may not sum to 100%, due to rounding up. 
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I. Abstract   
 
Objective: Early studies in Cape Town identified independent HIV-1 epidemics, with distinct 
viral subtypes, among men who have sex with men (MSM) and the heterosexual population. 
However few recent HIV-1 subtype data are available for MSM in South Africa. We 
examined circulating HIV-1 subtypes among MSM in Cape Town.    
Design: Cross-sectional survey 
Methods: Self-identified MSM were recruited from geographically and racially disparate 
communities across Cape Town. Participants completed behavioural questionnaires and 
underwent HIV testing. Virus isolated from infected participants underwent complete env 
gp160 sequencing and HIV-1 subtypes were assigned via phylogenetic analysis.  
Results: In total 194 HIV-infected MSM were enrolled: 67% black African, 24% coloured, 
and 9% white men. More black African men identified as bisexual or heterosexual compared 
to other races. Overall 31% - 66% of men reported a recent partner of another race. HIV-1 
subtypes were confirmed for 143 participants: 81% were subtype C, 14% B, 1% A1, 1% F2, 
and three recombinant viruses.  Subtype C virus was associated with black African race 
(p=0.003 compared to coloured; p<0.001 compared to white), men who identified as 
bisexual/heterosexual (p=0.01), and reported a female sexual partner in the last year 
(p=0.02).  Compared to previous studies, an increasing prevalence of subtype C virus was 
noted among white MSM. 
Conclusions: This molecular epidemiological study provides novel evidence of sexual 
network links between the heterosexual and MSM epidemics and between historically 
racially disparate communities. These findings provide insights into the drivers of HIV 
epidemics in different population groups and may have implications for prevention strategies.  
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South Africa has one of the largest HIV epidemics world-wide, with an estimated prevalence 
of 17% [1]. The first documented South African cases of acquired immunodeficiency 
syndrome (AIDS) were identified in men who have sex with men (MSM) in 1982 [2], and the 
HIV prevalence among primarily white MSM peaked in the mid-1980s [3]. However by the 
early 1990s it was clear that this MSM epidemic was rapidly giving way to a far larger 
heterosexual epidemic, predominantly among black Africans who comprise the majority of 
the South African population [4]. An early molecular epidemiological study of circulating HIV 
strains in Cape Town in the late 1980s and early 1990s suggested that the two epidemics 
were independent of one another: the MSM epidemic was comprised almost exclusively of 
HIV-1 subtype B virus, and was associated with travel to high income countries [5]. The 
heterosexual epidemic, by contrast, comprised mainly HIV-1 subtype C virus and most likely 
spread to South Africa through local or regional travel [5].  
 
Independent HIV epidemics in different population groups have also been identified in 
Thailand, and it has been postulated that the “epidemiological segregation” of subtypes may 
be due to demographic and social network factors that extend beyond sexual preference [6]. 
Indeed, the importance of societal structures has also been noted in the spread of other 
sexually transmitted diseases in South Africa [7].  In South Africa, the political segregation of 
apartheid, including legally enforced racial segregation of residential areas and prohibition of 
inter-racial sexual relationships may have limited social mixing and amplified this 
phenomenon. Furthermore, the different cultural backgrounds of South African MSM 
communities may influence how these groups identify and engage in MSM activity, as well 
as the interaction across these communities [8].   
 
The current emphasis of HIV prevention and treatment policies and research programmes in 
South Africa are overwhelmingly focused on heterosexual and vertical transmission of HIV. 
As a result, research among MSM, and HIV prevention policies for this group have been 
largely neglected. Yet, there is evidence that HIV prevalence remains high in MSM groups in 
South Africa [9]. While the impact of MSM transmission of HIV on the South African 
epidemic may be minor, these transmission patterns may contribute disproportionally to 
incident HIV infections among males generally [10].  
 
Little is known about the HIV-1 subtypes currently circulating among MSM in Cape Town or 
indeed in South Africa, or how the changing socio-political landscape over the past two 












testing, transmission, natural history of the disease, treatment and prevention, particularly 
HIV vaccine designs [11,12]. We aimed to describe the circulating HIV-1 subtypes among 
MSM in Cape Town, and explore possible differences and links between both the 




Participants: Self-identified MSM were recruited from urban and peri-urban sites in Cape 
Town in 2009 and 2010, over an eight-month period. Historically, Cape Town was divided 
into geographical, racially-defined areas [13]. For the purposes of this study, urban areas 
were defined as Cape Town’s Central Business District (CBD) and surrounding communities 
that were historically designated as white communities. Peri-urban areas were defined as 
township or low-income communities that were historically designated as black African 
and/or coloured communities. The racial categories of black African, coloured and white 
were used as per the terms employed in the latest South African census [14]. In South 
Africa, “coloured” refers to individuals of mixed race or of Khoisan or Malay descent [15]. 
Participants were recruited from organizations and venues frequented by MSM, subsequent 
referrals from enrolled participants (quasi-snowballing technique [16]), and recruitment via 
other studies and internet advertising. Men were considered eligible for the study if they 
were of male sex at birth, 16 years of age or older, resided in the greater Cape Town area, 
had engaged in sexual activity with another man in the last 12 months and were willing to 
undergo an HIV test. 
 
Following enrollment, participants completed interviewer-administered questionnaires in their 
home language that captured demographic data and information on sexual orientation and 
disclosure. Information was also gathered on participants’ sexual history, in particular 
regarding sexual history with female partners, as well as the participant’s three most recent 
sexual partners in the past six months. HIV testing was performed using finger-prick rapid 
antibody screening tests and followed the national HIV Counselling and Testing guidelines 
[17]. Men who tested HIV-positive had blood samples drawn for CD4 T-cell count testing and 
HIV subtyping. The study was conducted in accordance with the Declaration of Helsinki 
(2008) and was approved by the Human Research Ethics Committee of the University of 
Cape Town. Participants provided written informed consent. 
 
In order to show a 25% difference in the representation of subtype C virus among MSM in 












an approximately 15% loss of specimens due to difficulties in amplification of cDNA or 
indeterminate sequencing results.   
 
Viral RNA extraction, cDNA synthesis and amplification: HIV-1 subtyping was performed 
by DNA amplification followed by sequencing of the HIV-1 env gene. RNA was extracted 
from 200-400µl plasma using the QIAamp Viral RNA Mini Kit (Qiagen). Reverse transcription 
of RNA to single-stranded cDNA was performed with SuperScript III Reverse Transcriptase 
using primer Oligo (dT)20 (Invitrogen Life Technologies) based on manufacturer-
recommended, previously described methods [18].  
 
In order to ensure that single genomes were amplified, cDNA was serially diluted to 
determine the exact dilution at which no more than 30% positive amplification reactions was 
present per dilution batch. Amplification of gp160 was then performed according to a method 
described elsewhere [19].  
 
For Gag p17p24 amplification and sequencing a One-Step RT-PCR was performed 
(SuperScript® III One-Step RT-PCR System with Platinum® Taq DNA Polymerase High 
Fidelity, Invitrogen Life Technologies), which was adapted from a method described 
elsewhere [20]. This consisted of 1x Reaction Mix (0.2 mM of each dNTP and 1.6mM 
MgSO4), 0.2µM of each primer DT1 5’ ATGGGTGCGAGAGCGTCAGTATT ‘3 (nt 790-812 
HXB2) and DT7 5’ CCCTGACATGCTGTCATCATTTCTTCT ‘3 (nt 1818-1844 HXB2), and 
1µl of the SuperScript® III RT/ Platinum® Taq Mix in a 50µl reaction. PCR cycling 
parameters were: 1 cycle of 55°C for 30 minutes; 1 cycle of 94°C for 2 minutes, 10 cycles of 
a denaturing step of 94°C for 15 seconds, an annealing step of 55°C for 30 seconds, an 
extension step of 68°C for 1 minute; 25 cycles of a denaturing step of 94°C for 15 seconds, 
an annealing step of 55°C for 30 seconds, an extension step of 68°C for 1 minute with a 5 
second increase for each cycle thereafter and followed by a final extension of 68°C for 7 
minutes. The second round PCR consisted of 1x Expand High Fidelity Buffer, 1.5mM MgCl2, 
0.2 mM each dNTP, 0.3µM of each primer DT3 5’ CATCTAGTATGGGCAAGCAGGGA ‘3 (nt 
886-908 HXB2) and DT6 5’ ATGCTGACAGGGCTATACATTCTTAC ‘3 (nt 1609-1634 
HXB2), and 2.6 units Expand High Fidelity polymerase (Roche) in a 100µl reaction. Second 
round cycling parameters: 1 cycle of 94°C for 2 minutes; 10 cycles of 94°C for 15 seconds, 
57°C for 30 seconds, 72°C for 1 minute; 25 cycles of 94°C for 15 seconds, 57°C for 30 
seconds, 72°C for 1 minute with 5 seconds increase per cycle; 72°C for 7 minutes.   
 
Sequencing and Sequence Analysis: PCR products were directly sequenced using 












Foster City, CA). The sequences were determined by using an ABI 3730xl genetic analyzer 
(Applied Biosystems, Foster City, CA) and edited by using the Sequencher program (Gene 
Codes, Ann Arbor, MI).  
 
The complete env gp160 sequences (~2500bp) of study participants were aligned using 
CLUSTAL W [21], and subtypes were assigned by inferring gp160 phylogenetic relatedness of 
participant sequences to an HIV-1 subtype reference set from the HIV Sequence Database 
[22]. Maximum Likelihood phylogenetic trees were generated using MEGA v5.04 software 
[23] based on the  Tamura-Nei model [24]. Reliability of the tree topology was assessed by 
500 bootstrap replicates. Sequences which clustered together were further investigated to 
exclude any possibility of contamination or sample mix-up. Sequences from all phylogenetic 
clusters were confirmed by re-isolation of RNA and sequenced in gp160 and/or a region in 
gag p17p24 (748 bp). In all cases except one (in which clustering could not be confirmed in 
gag), cluster patterns were confirmed true.   
 
Sequences were screened for evidence of inter-subtype recombination by the 
Recombination Identification Program (RIP 3.0) 
(http://www.hiv.lanl.gov/content/sequence/RIP/RIP.html), REGA HIV-1 Subtyping Tool-
Version 2.0 (http://www.bioafrica.net/rega-genotype/html/subtypinghiv.html) and jumping 
profile Hidden Markov Model (jpHMM) (http://jphmm.gobics.de/) [25]. Recombinant viruses 
were analyzed for subtype assignment and breakpoint identification by SimPlot software 
v3.5.1 (http://sray.med.som.jhmi.edu/SCRoftware). Specifically, neighbour-joining bootscan 
analysis was performed with a sliding window of 200 bp incremented by 20 bp across the 
entire alignment that included sequences of nine HIV-1 subtypes—A, B, C, D, F, G, H, J, 
and K, obtained from the Los Alamos HIV database (http://www.hiv.lanl.gov/). Phylogenetic 
trees were generated from portions of gp160 on either side of Simplot identified breakpoints 
in order to confirm HIV-1 inter-subtype recombinant viruses.  
  
Data were analyzed using STATA 10.0 (StataCorp, College Station, Texas). Bivariate 
analyses employed Wilcoxon rank sum, chi-squared tests and Fisher exact tests, as 
appropriate. Bivariate and multivariate logistic regression models were developed to 

















In this study, 197 HIV-infected MSM were enrolled. Three participants were subsequently 
excluded: one was confirmed ineligible, and two were enrolled twice in the study (data from 
second enrolment were excluded). Of the remaining 194 participants, 93 (48%) were from 
urban areas.  
 
Demographics and sexual history 
The median age of participants was 32 years (interquartile range [IQR]: 26-39), and 47 
(25%) were employed. Overall 129 (67%) were black African, 47 (24%) were coloured, and 
17 (9%) were white men. The demographic characteristics, sexual orientation and 
relationship histories are reported by race (Table 1). In total 72% of men identified as 
homosexual or gay, 21% identified as bisexual, and 3% as heterosexual. Black men were 
more likely to identify as bisexual or heterosexual compared to other races (33% compared 
to 6% in both coloured and white men; p<0.001). Black men were less likely to have 
disclosed their same sex activity to family or friends compared to coloured and white MSM 
(p=0.01). 
 
Overall, 96 (49%) men reported having a female sexual partner in the past, with black 
African and white men more likely to have ever had a female partner compared to coloured 
men (p<0.001). Overall, 50% of participants were currently in a relationship with a man, 9% 
with both a male and a female partner, 5% with a female partner, and 36% were not 
currently in a relationship. Black men were more likely to be in relationship with both men 
and women (not statistically significant). When asked about their three most recent male 
sexual partners, 31% (95% confidence interval [CI]: 10-61%) of white participants, 66% 
(95% CI: 50-80%) of coloured and 32% (95% CI: 24-41%) of black participants reported a 
partner of a different race. 
 
HIV-1 subtypes 
HIV-1 subtypes were confirmed phylogenetically for 143 of the 194 participants. There was 
no difference in those participants with and without subtyping data in terms of residential 
location (p=0.42), race (p=0.51) or previous or recent female sexual partner (p=0.22 and 
p=0.87, respectively). However, participants who identified as homosexual/gay were more 
likely to have subtyping data available (p=0.01). Overall 116 (81%) samples were subtype C, 
20 (14%) subtype B, two (1%) were subtypes A1, two (1%) F2, and three (3%) were 












distribution of HIV subtypes among racial groups are shown in Figure 1. In total, 85% of 
participants with subtype B virus and 43% of those with subtype C were from urban sites.  
 
The phylogenetic trees for the viruses in each race group are presented in Figure 2.  
Subtype C virus was more likely to occur in black African men (odds ratio [OR]: 4.5; 95% 
CI:1.7-12.5 compared to coloured men and OR:18.8; 95% CI: 4.5-78.3 compared to white 
men) and men who identified as bisexual/heterosexual (p=0.01). While subtype C was not 
associated with a previous history of female sexual partner, it was associated with a female 
sexual partner in the last year (OR: 6.8; 95% CI: 01.4-33.3 “within last year” compared to “>1 
year ago”).  The association of demographic, sexual orientation and sexual history with 
subtype C is reported in Table 2.  When adjusted for location, race (p=0.001) remained 
positively associated with subtype C virus, but location did not (p=0.39).  Among white men, 
the median age of individuals with subtype C virus was 34 years (IQR:27-41) versus 40 
years (IQR: 36-40) among men with subtype B (p=0.77). 
 
Some subtypes and recombinant forms that occur at low frequencies globally were detected, 
including two subtype F2 viruses in black African men and one BF recombinant virus in a 
white man. The subtype F2 viruses clustered with viruses from Cameroon and were very 
closely related to each other (Figure 3) suggestive of recent transmission from a common 
source in South Africa rather than two independent introductions of this subtype into the 
community. The participant with BF virus reported recently returning from Dubai, where he 
had had at least two sexual partners. Two additional recombinant strains were identified, 
namely recombinant AC (from a black participant) and BC (from a coloured participant). Both 
these participants reported no sexual history with a woman, and reported that their last three 
sexual partners were all in South Africa. The three recombinant viruses were not recognized 
circulating recombinant forms (CRFs). 
 
In addition to the F2 cluster, there were a further 17 participants in seven clusters of low 
diversity (range: 2-4 individuals/cluster) suggestive of recent transmission events (Figure 3).  
From the available sexual network data, possible epidemiological links were identified 
between 15 (79%) participants occurring in clusters (ie, reported residing in or having recent 
sexual partners from the same communities), and no epidemiological link was found for the 
remaining four participants. While there were no differences in race within clusters, in three 















In the early 1990s studies reported two independent HIV-1 epidemics in Cape Town: a 
predominantly subtype B epidemic among MSM and a subtype C epidemic in the 
heterosexual population [5,26].  While a number of studies have assessed the circulating 
HIV subtypes of predominantly the heterosexual epidemic since then [27-29], this study is 
the first dedicated study of subtypes among MSM in Cape Town in the last two decades. 
This study demonstrates that the two epidemics are no longer independent, and reports 
evidence of bridging between the generalized heterosexual and concentrated MSM HIV 
epidemics in Cape Town.  
 
While subtype B virus remains more prevalent among MSM compared to the generalized 
epidemic (14% vs 1-7% respectively [29-31]), the majority of MSM in this study had subtype 
C virus. Subtype C was significantly associated with men from peri-urban locations, and 
more specifically with black African race. Subtype C was also strongly associated with 
bisexual orientation as well as reported sex with a female in the last year.  We found that half 
of the self-identified MSM participants reported high levels of sex with women. In particular, 
black African MSM were more likely to identify as bisexual or heterosexual compared to 
white or coloured MSM, and were more likely to have a current female partner. This may be 
related to the finding that black African men were less likely to have disclosed their sexual 
preference to anyone, possibly due to high levels of stigma and discrimination within these 
communities [32]. Together, the higher levels of bisexual activity and the association with 
subtype C virus among black African MSM may be evidence of bridging between the 
heterosexual and homosexual populations in Cape Town. This hypothesis is strengthened 
by reports of an increasing representation of subtype B in South Africa’s heterosexual 
population [29]. In addition, two of the three recombinants detected in this study included 
subtype C sequences (including one BC sequence), further supporting the theory of bridging 
between the MSM and heterosexual epidemics. This finding is in keeping with literature from 
Kenya where it has also been reported that MSM are predominantly infected with the same 
HIV subtype as the general population [33]. 
 
While predominately associated with black African MSM, an increasing prevalence of 
subtype C virus was noted among white MSM – no subtype C viruses were identified among 
this group in the 1990s [5], but subtype C accounted for 36% of HIV infections among white 
MSM in this study. A trend toward subtype C virus occurring in younger white MSM was also 
noted, although this was not statistically significant (possibly due to the small sample size in 












finding may reflect a breaking down of historical social barriers in Cape Town in the recent 
past, with mixing across previously racially defined urban and peri-urban communities, and a 
bridging of epidemics across these districts.  
 
Research from Cape Town over the past decade have reported overwhelmingly subtype C 
epidemics (>90%) with variable representation of subtypes B, as well as A and G (one study 
each) and occasional recombinants [31,34]. This study reported an unusually high diversity 
of HIV subtypes. These subtypes may have been introduced to Cape Town MSM networks 
through international tourism [5] and the migration of other African MSM to South Africa, 
seeking the protection afforded by the country’s constitution. Furthermore, while there were 
insufficient specimens to exclude a founder effect among subtype B viruses, the lack of 
structure among the subtype C component of the overall phylogenetic tree is evidence of the 
absence of a founder effect in this group. This is in keeping with literature that suggest 
multiple introductions of subtype B and C viruses into South Africa [5,31].   
 
This study has several limitations. First, due to the hard to reach nature of the MSM 
population, a number of recruitment strategies were used, as is commonplace when working 
with MSM [16], and this non-random recruitment strategy may limit the generalizability of our 
findings. Behavioural data was obtained by interviewer-administrated questionnaire, and 
may suffer from typical problems of self-reported information, including social desirability 
bias. Due to the cross-sectional study design we are more likely to have identified prevalent, 
rather than incident HIV-positive cases, limiting our ability to make inferences regarding 
currently circulating HIV-1 strains. The large number of linked cases identified in this study 
may be due to the high frequency of multiple concurrent partners among MSM [35,36]. In 
this study, the evidence of possible recent transmission links may be a result of the peer-
based recruitment strategy. However we were unable to confirm transmission events, as we 
did not collect in-depth sexual network data. Furthermore, we did not investigate the likely 
route of HIV acquisition. It is possible that some participants acquired HIV infection through 
non-sexual routes, such as blood transfusions or intravenous drug use (IDU). However IDU 
is reportedly low (<3%) among South African MSM [32].  
 
In conclusion, this study presents novel data on the molecular epidemiology of HIV-1 
subtypes among MSM in South Africa.  A substantially higher proportion of subtype C 
infections was found in this sample compared to previous studies and evidence of 
transmission of relatively rare subtypes such as F2 and BF recombinants was also found. 
These data provide biological confirmation of behavioural data of the links between the 












communities in Cape Town, and providing insights into the drivers of HIV epidemics in 
different population groups. As the generalized HIV epidemic stabilizes emphasis is shifting 
towards “hot-spot” populations and this study illustrates the value of molecular epidemiology 
for understanding sexual networks and transmission dynamics in key groups. Public health 
implications of this study’s findings include informing HIV prevention strategies such as risk 
reduction counselling. Counsellors should be trained to enquire and counsel men about 
same-sex activity, even if married or reporting relationships with members of the opposite 
sex. These findings may also have implications for ongoing HIV-related research, particularly 
the development of locally efficacious HIV vaccines. Over the next several years, vaccine 
products based on subtype C constructs will be entering clinical trials, including in South 
Africa.  Given that MSM who report sex with women have a significant risk of subtype C 
infection, they should be eligible for participation in these studies. 
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Table 1: Demographic, sexual orientation and relationship history, reported by race 
 Black African Coloured White p-value 
 n=129 n=47 n=17  
 
n(%) or 
 median (IQR) 
n(%) or 
 median (IQR) 
n(%) or 
median (IQR)  
Demographics     
Age 32 (25-37) 32 (26-38) 40 (32-42) <0.001 
Peri-urban 91 (71) 10 (21) 0 <0.001 
Employed 19 (15) 16 (34) 11 (65) <0.001 
Education level     
   No secondary level education 12 (9) 8 (17) 0  
   Secondary level education 91 (71) 29 (62) 9 (53)  
  Tertiary education 26 (20) 10 (21) 8 (47) 0.13 
     
Sexual Orientation     
 Heterosexual/Straight 5 (4) 1 (2) 0  
 Homosexual/gay 83 (66) 39 (83) 15 (88)  
 Bisexual 37 (29) 2 (4) 1 (6)  
 Other  1 (1) 5 (10) 1 (6) <0.001 
     
Sexual History     
Have ever had sex with a 
woman 76 (59) 9 (19) 10 (59) <0.001 
Had sex with a woman in the 
last year 42 (58) 3 (30) 0 <0.001 
Current relationship status     
 Male partner 67 (52) 19 (40) 10 (63)  
 Female partner 7 (5) 2 (4) 0  
 Both male and female partner 17 (13) 1 (2) 0 0.26 
     
 Not in a relationship 38 (30) 25 (53) 6 (38) 0.02 
     
Disclosed sexual involvement 
with other men to anyone 89 (69) 38 (81) 17 (100) 0.01 
Columns may not always sum to n, due to missing data points  
One participant declined to identify his race and is therefore excluded from this table (n=193). 













Table 2: Demographic, sexual orientation and relationship factors associated with subtype C 
virus. 
 Bivariate analysis p-value 
Association with subtype C OR (95% CI)  
   
Demographics   
Age 0.96 (0.9-1.0) 0.08 
Location   
   Urban 1  
   Peri-urban 4.6 (1.7-12.3) 0.002 
Race   
  White  1  
  Coloured  4.1 (1.0-17.1) 0.05 
  Black African 18.8 (4.5-78.3) <0.001 
Employed 0.2 (0.1-0.6) 0.001 
   
Sexual orientation   
  Homosexual 1  
  Bisexual/heterosexual *  
   
Sexual history   
Ever had sex with a woman 1.1 (0.5-2.5) 0.88 
Last sexual intercourse with a woman   
  More than 1 year ago  1  
  Within last year 6.8 (1.4-33.3) 0.02 
Currently in relationship   
  With a man 1  
  With a woman 1.8 (0.2-15.9) 0.59 
  With a man and a woman *  
   
Disclosed sexual involvement with other 
men to anyone 
0.1 (0.01-0.7) 0.03 
* Perfectly predicts subtype C infection  
OR = odds ratio 












Figure 1: Consort diagram of subtyping data, by race 
 
 












Figure 2: Maximum likelihood trees of study sequences together with 19 reference 
sequences (obtained from the HIV Sequence Database) presented by race. The scale bar 
represents 2% divergence. Proportional representation of subtypes in black African (A), 













Figure 3: Gp160 Maximum likelihood tree depicting phylogenetic relatedness of the 143 
MSM study sequences.  Eight putative clusters are bolded.  The scale bar represents 2% 
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I. Informed Consent    
MSM HIV Subtype Study 
Informed Consent 
Version 1.0 
18 Apr 2013 
 
Epidemiology of HIV-1 subtypes among Cape Town MSM 
An Exploratory Study to Determine Identity, Social Networks and Circulating HIV Subtypes 
Among Men Who Have Sex With Men in Cape Town 
 
Dear Participant 
The Desmond Tutu HIV Foundation is conducting a study to gain an improved understanding 
of men-who-have-sex-with-men (MSM) in the greater Cape Town area.  You are being invited 
to participate in this study because you have identified yourself as a man who has sex with 
men. This information leaflet describes the study.  Please ask a member of the research team 
any questions you may have regarding the study. The doctor in charge of this study is Dr 
Keren Middelkoop. 
 
Participation in this study is voluntary. You can refuse to take part in this study. 
 
Why are we doing this study? 
We wish to better understand the social and sexual networks among MSM in the greater Cape 
Town area. In addition we are studying the main HIV subtypes in HIV-positive MSM in this area.  
There are several different types of HIV virus.  We call these “subtypes”.  You can think of them 
as “cousins” in the same family.  Scientists think that the type most commonly transmitted by 
heterosexual contact may be different from the type most commonly transmitted by MSM 
contact in South Africa.    
 
We hope that this information will help to develop local policy and HIV prevention strategies, 
particularly for the MSM communities.  
 
Who can take part in the study? 
This study will include men who were born male, identify themselves as MSM and are 16 
years or older.  All study participants should reside in the greater Cape Town area, and must 
either have a documented HIV-positive test result or be willing to have an HIV test as part of 













What will the participants need to do on the study? 
If you take part in this study we will ask you to: 
- Answer a questionnaire that will ask about basic demographic details, your 
sexual orientation and past and current sexual partners. 
o The questionnaire will take about 30 minutes to complete.  
- You will have about 20ml of blood drawn (approximately 2 tablespoons) for: 
o  an HIV test 
 You will get the results back at the same visit 
 
- If you test HIV-negative: 
o You will receive post-test counselling, including risk reduction counselling 
o The remaining blood drawn from your arm will be discarded. 
- If you test HIV-positive: 
o You will have a second HIV test to confirm the diagnosis 
o  you will receive post-test counselling 
o Some of your blood will be stored for HIV-subtype testing 
o We will also send some of your blood for a CD4 count test. You may 
come back for a second visit to receive further counselling and get your 
CD4 result. 
o We will refer you to an appropriate centre for medical care. 
 
This part of the study will take approximately another hour. 
 
Where does your blood go? 
The blood for the CD4 count will be sent to a local laboratory for testing.  The blood for the HIV 
subtyping will be sent to a research laboratory at the University of Cape Town.  The blood will 
be labeled only with your unique study number and not with your name to be sure that no one, 
other than the clinical staff, know who you are. 
 
What about confidentiality? 
All information you give us and all results of laboratory tests will be kept private and will only be 
disclosed to your medical care provider with your permission.  Your name will not be written on 
the questionnaire.  The completed consent forms will be kept in a separate locked filing cabinet 
that can only be opened by the study staff.  Your name will not be used in any publication or 
presentation of this study.  
Your study records may be reviewed by study staff and study monitors, as well as 












What are the possible risks of this study? 
Some questions in the questionnaire might make you feel uncomfortable.  You have the right 
to refuse to answer any question.  Another risk is that confidentiality may be broken.  We 
cannot guarantee participant’s confidentiality, but every effort will be made to protect 
confidentiality. 
There is some risk in drawing blood from a vein for the laboratory tests.  You will probably 
have pain and may have some bruising where the needle goes into your arm.  Very rarely, 
you may develop an infection at the site of the blood draw.   
 
What are the benefits of the study?  
You will benefit by learning your HIV status.  You will receive risk reduction counselling.  If you 
are HIV-positive you will receive the results the CD4 test and you will be referred for appropriate 
medical care.  The knowledge that we gain from this study may help with HIV research, 
treatments, and prevention strategies. 
 
What are my rights during the study? 
Participation in the study is voluntary.  You are free to withdraw from the study at any time 
without any disadvantage to you.  Participants can decide at any time to leave the study after 
starting.  In this case we will ask the reasons for no longer wishing to be part of the study. 
 
Will being in the study cost anything? 
Participation in the study will not cost you any money. 
 
Will I be paid to be in this study? 
No, you will not be paid.  You will be given R100 to reimburse you for time and transport. 
 
What are my alternatives? 
You can chose not to take part in this study. If you are concerned that you have HIV you can 
get tested at any HIV testing clinic or centre. The researcher can give you more information 
as to your closest available testing centre. 
 
Who do I call if I have questions? 
If you need more information or you have any questions regarding the study, please feel free 
to contact Dr Keren Middelkoop, Desmond Tutu HIV Foundation at 021 650 6966. 
 
If you have a question about your rights as a research volunteer you can contact Dr 
Blockman at 021 406 6492.  He is the head of the University of Cape Town Human 












Epidemiology of HIV-1 subtypes among Cape Town MSM 
An Exploratory Study to Determine Identity, Social Networks and Circulating HIV Subtypes 
Among Men Who Have Sex With Men in Cape Town 
 
Consent Form 
I hereby confirm that I have been told about the design and purpose of this study.  I have 
received and understood the above information regarding the research.  I understand that 
my participation in the study is voluntary.  I have had sufficient opportunity to ask questions 
and my questions have been answered.  I agree to participate in the research as described 
in the information leaflet above. 
 





Printed Name     Signature   Date 
 
Study Staff Member’s Name: 
 
 
Printed Name     Signature   Date 
 
Witness’s Name (if appropriate): 
 
 














II. Study Questionnaire     
 Epidemiology of HIV-1 subtypes among Cape Town MSM  
Study Questionnaire 




88 Unsure/don’t know 




1 How old are you? Number of Years  
2 What race do you identify as? 
 
1 Black African 
2 Colored 
3 White 
4 Other (specify) 
 
3 Which township or suburb do you live in? Name 
4 How long have you lived in this township/suburb? Number of Years 
5 Which township or suburb do you live in before you moved here? Name 
6 What level of education have you completed? 1 No formal Education 
2 Primary School 
3 Secondary School 
4 College or University 
 
7 Are you currently employed/working? 1 Yes 
2 No 
 




3 Both a male & a female 
77 Not married or in a 
relationship 
 





If YES to 9, When did you last have vaginal sex with a woman? 
 
 
1 This week 
2 This month 
3 In the last 6 months 
4 In the last year 
5 Over a year ago 
 










4 Other (specify) 
 
13 Have you told anyone about your sexual involvement with other men?  
 
If YES to 14:, Choose all options that apply 
1 yes 
2. No  
 
1a Family member 
1b Gay Friends 
1c Straight Friends 
1d Wife/girlfriend 
1e Casual girlfriend 
1f Co-worker 
1g Religious leader 

















I’m now going to ask about the 3 most recent partners you have had sex with in the last 6 months.  
You do not have to use any names. 
Let’s start with the MOST RECENT partner you have had sex with in the last 6 months. 
 Question Response Guide 1st Partner 2nd Partner 3rd Partner 





   
15 What is the race or ethnic 
group of this partner? 
1 Black African 
2 Colored 
3 White 
4 Other (specify) 
   
16 Was/Is this partner a main or 
casual partner?  
1 Main 
2 Casual 
   
17 Where did you meet this 
partner? 
 
(name township/suburb)    
18 Where does this partner 
live? 
(name township/suburb) 
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